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OBJECTIVES We sought to assess whether hyperenhancement by gadolinium cardiovascular magnetic
resonance (CMR) occurs in hypertrophic cardiomyopathy (HCM) and correlates with the
risk of heart failure and sudden death.
BACKGROUND The myocardial interstitium is abnormal in HCM at post-mortem. Focally increased
interstitial myocardial space appears as hyperenhancement with gadolinium CMR.
METHODS In a blinded, prospective study, HCM patients were selected for the presence (n  23) or
absence (n  30) of an increased clinical risk of sudden death and/or progressive adverse left
ventricular (LV) remodeling. Gadolinium-enhanced CMR was performed.
RESULTS Myocardial hyperenhancement was found in 42 patients (79%), affecting 10.9% (range 0% to
48%) of the LV mass. There was a greater extent of hyperenhancement in patients with
progressive disease (28.5% vs. 8.7%, p  0.001) and in patients with two or more risk factors
for sudden death (15.7% vs. 8.6%, p  0.02). Improved discrimination was seen in patients
40 years old (29.6% vs. 6.7%, p  0.001) for progressive disease and for patients 40 years
old for risk factors for sudden death (15.7% vs. 2.1%, p  0.002). Patients with diffuse rather
than confluent enhancement had two or more risk factors for sudden death (87% vs. 33%, p
0.01).
CONCLUSIONS Gadolinium CMR reveals myocardial hyperenhancement in HCM. The extent of hyperen-
hancement is associated with progressive ventricular dilation and markers of sudden
death. (J Am Coll Cardiol 2003;41:1561–7) © 2003 by the American College of
Cardiology Foundation
An important minority of patients with hypertrophic
cardiomyopathy (HCM) are at high risk of sudden death
and/or progressive left ventricular (LV) impairment
(1,2). Predicting these outcomes is a major manage-
ment challenge, and new methods are needed. The ab-
normal myocardial substrate is probably the key determi-
nant of clinical events (3–6), consisting of interstitial
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fibrosis, myocardial disarray, small-vessel disease, and
macroscopic scarring. Fibrosis caused by myocardial infarc-
tion can be detected by cardiovascular magnetic resonance
(CMR) using the extra-cellular fluid tracer gadolinium-
diethylenetriaminepentaacetic acid (DTPA), or gadolinium
CMR (7–9). We hypothesized that abnormal myocardium
would be demonstrated in vivo by hyperenhancement on
gadolinium CMR in HCM and that hyperenhancement
would be associated with markers of risk of sudden death
and the presence of progressive disease.
METHODS
Patients. This was a blinded, prospective study of 53
patients selected from a dedicated HCM clinic at St.
George’s Hospital, London, which consists of 1,074 pa-
tients. The selected patients fulfilled conventional criteria
for HCM with left ventricular hypertrophy (LVH)
15 mm at some time point in their disease (10). The only
exclusion criterion was the presence of an implantable
device. We aimed to recruit approximately equal numbers of
patients with two or more risk factors or progressive disease,
as those without these factors. Four patients had undergone
gradient reduction therapy (two surgical myectomies and
two transcatheter alcohol ablations). All patients gave writ-
ten, informed consent, and the institutional Ethical Review
Committee approved the study.
Sudden death risk stratification. Five clinical risk factors
for sudden death were used to stratify patients: a family
history of HCM and sudden premature cardiac death;
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unexplained syncope at any time during follow-up; non-
sustained ventricular tachycardia; an abnormal blood pres-
sure response during upright exercise testing in subjects
40 years old; and echocardiographic presence of severe
LVH 30 mm.
Diagnosis of progressive disease. Progressive disease was
defined as a decrease in maximal LV wall thickness 5mm
and an increase in LV end-systolic dimension 5mm
during five or more years of follow-up on a serial in-house
echocardiogram. This definition selects a poor prognostic
group, including patients with “pseudonormalization” of
initial supra-systolic function and LVH on the way to a
dilated phase.
The CMR technique. CMR was performed on a 1.5-T
Sonata scanner (Siemens, Erlangen, Germany). Fast imag-
ing with steady-state precession (FISP) sequential short-
axis cine loops (7-mm slice thickness, 3-mm gap) were
acquired. A peripheral bolus injection of gadolinium-
DTPA (0.1 mmol/kg) was then given, and contrast-
enhanced images were acquired using a segmented
inversion-recovery sequence (11), with the following mod-
ifications: imaging was started at 5 min; segmentation was
from 17 to 23 lines; inversion pulse every 2 to 3 heart beats
depending on the RR interval and heart rate variability; a
90° presaturation pulse was placed over the cerebrospinal
fluid to eliminate ghosting; and two-chamber, four-
chamber, and all short-axis views were acquired twice with
different phase-encoding direction and meticulous attention
to the inversion time. The typical voxel size was 1.7  1.4
 8 mm.
Image analysis. Ventricular function was analyzed from
the serial short-axis true FISP cine loops using manual
segmentation (CMRtools Imperial College, London). End-
diastolic volume, end-systolic volume, ejection fraction, and
myocardial volume of the LV were calculated. For the
gadolinium-enhanced images, hyperenhancement was only
considered to be present if it was also present in the same
slice after swapping phase encoding, thus excluding artifact.
Analysis was performed by manually defining the areas of
hyperenhancement on all short-axis slices from the base to
apex. Summing the areas yielded the total volume of
hyperenhancement, which was expressed as a percentage of
total myocardium.
Statistical analysis. Non-parametric Wilcoxon rank com-
parisons were made to compare the extent of hyperenhance-
ment between patients with 1 and 2 risk factors for
sudden death, and between patients with and without the
presence of progressive disease. Linear regression analysis
was performed to compare the extent of hyperenhancement
with patient age, LV function, and mass.
RESULTS
Patient baseline characteristics. The baseline characteris-
tics of the patients are given in Table 1. There were 0, 1, 2,
3, 4, and 5 risk factors in 19, 16, 13, 3, 2, and 0 patients,
respectively. Of 34 patients with 5 years of follow-up,
nine had progressive disease (of these, four patients also had
2 risk factor for sudden death). There was no age
difference between patients with and without progressive
disease (49 vs. 51 years, p  0.8), but patients with 2 risk
factors for sudden death were younger than patients with
1 risk factors for sudden death (35 vs. 53 years, p 
0.001).
Extent of hyperenhancement. Myocardial hyperenhance-
ment was present in 42 patients (79%). The mean percent-
age of myocardium involved was 10.9  11% (range 0% to
48%). Abnormal myocardium was not visible without con-
trast (Fig. 1). Regions of hyperenhancement had a mean
image intensity of 27; remote myocardium, 5.7; and back-
ground noise, 4.24. The percentage elevation in signal from
hyperenhanced regions was 430% (range 120% to 1,000%);
the mean difference in image intensity between hyperen-
hanced and remote regions was 16 standard deviations of
remote region intensity. There was no relationship between
percentage hyperenhancement and patient age (r 0.1, p
0.47). The percentage hyperenhancement correlated weakly
with LV mass index (r  0.24, p  0.04), end-diastolic
Abbreviations and Acronyms
CMR  cardiovascular magnetic resonance
DTPA  diethylenetriaminepentaacetic acid
FISP  fast imaging with steady-state precession
HCM  hypertrophic cardiomyopathy
LV  left ventricle/ventricular
LVH  left ventricular hypertrophy
Table 1. Demographics and Baseline Characteristics
Characteristics
Age (yrs) 47  16 (range 15–73)
Male gender 37 (70%)
Years since diagnosis 12  10
Years of local echocardiographic follow-up 7  5
NYHA functional class
I 30 (57%)
II 21 (40%)
III 2 (3%)
FH of HCM and 2 sudden deaths 11 (21%)
Unexplained syncope 14 (26%)
NSVT on Holter monitor 11 (21%)
Documented sustained VT/VF 3 (6%)
Abnormal exercise BP response 12 (23%)
Maximum LV wall thickness 30 mm 8 (15%)
Echocardiographic LV outflow gradient
(mean 43 mm Hg [range 30–100])
30 mm Hg 44 (83%)
30 mm Hg 9 (17%)
Data are presented as the mean value  SD or number (%) of subjects.
BP  blood pressure; FH  family history; HCM  hypertrophic cardiomyop-
athy; LV  left ventricle/ventricular; NSVT  nonsustained ventricular tachycardia;
NYHA  New York Heart Association; VF  ventricular fibrillation; VT 
ventricular tachycardia.
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volume (r 0.42, p 0.002), and end-systolic volume (r
0.64, p  0.001) and inversely with ejection fraction (r 
0.64, p  0.001).
There was more hyperenhancement in patients with
progressive disease than in those without (28.5% vs. 8.7%,
p  0.001) (Fig. 2A). This remained significant when
patients with 2 risk factors for sudden death were ex-
cluded (28.4% vs. 6.9%, p  0.04) (Fig. 2B). This finding
appeared more marked in patients 40 years old (29.6% vs.
6.7%, p  0.001) (Fig. 2C), and remained significant when
patients with 2 risk factors for sudden death were ex-
cluded (28.4% vs. 6.9%, p  0.04) (Fig. 2D). There was
greater hyperenhancement in patients with 2 risk factors
for sudden death (15.7% vs. 8.6%, p 0.02) (Fig. 3A). This
remained significant when patients with progressive disease
were excluded (12.0% vs. 5.3%, p  0.02) (Fig. 3B). This
finding appeared more marked in patients 40 years old
(15.7% vs. 2.1%, p  0.002) (Fig. 3C), which remained
significant when patients with progressive disease were
excluded (14.1% vs. 2.1%, p  0.003) (Fig. 3D).
Patterns of hyperenhancement. Specific patterns of hy-
perenhancement were evident. There were two broad pat-
terns: diffuse hyperenhancement and confluent hyperen-
hancement. Patients with diffuse (n  8) rather than
confluent (n  21) enhancement had 2 risk factors for
sudden death (87% vs. 33%, p  0.01). Further classifica-
tion could be made, but the number of patients is too small
to draw strong conclusions. The distributions are shown in
Figure 4 and Table 2.
DISCUSSION
Identifying patients at high and low risk is an important
but problematic aspect of the clinical management of
HCM, particularly with the availability of an effective but
not hazard-free treatment option—the implantable
cardioverter-defibrillator (12). Likewise, there are few
markers for the risk of heart failure before LV dysfunction
is evident (13,14). Neither the genotype nor the extent of
hypertrophy fully predicts the clinical risk (15–17). Ideally,
assessment would involve a global assessment of the under-
lying histology, the substrate for myocardial pump failure,
and arrhythmia. The histology consists of myocardial dis-
array (18) and small-vessel disease or replacement fibrosis
(19–21).
Gadolinium-enhanced CMR has been validated for
the detection of irreversible injury in myocardial infarction
(22). Hyperenhancement is considered to occur in areas
of expanded extracellular space. Gadolinium bound to
DTPA diffuses into the interstitial space between cells
but not across cell membranes. In fibrosis and extracel-
lular expansion, there is a greater extracellular space for
gadolinium-DTPA accumulation, and the distribution ki-
netics are slower than normal myocardium (8,9). These two
effects result in a delayed and persistently higher relative
concentration of gadolinium in areas in the heart where
extracellular tissue is abnormal. We therefore hypothesized
that this technique might prove useful in the clinical
assessment of the myocardial substrate in HCM. In
Figure 1. Pre- and post-contrast images demonstrating hyperenhancement. The pre-contrast images are the diastolic frames of fast imaging with
steady-state precession cine loops. In the post-contrast images, normal myocardium appears dark. There is a large area of septal hyperenhancement, with
additional papillary muscle hyperenhancement and subendocardial hyperenhancement of the lateral wall. The patient is a 33-year-old female with two risk
factors for sudden death. Eight years previously, echocardiography demonstrated marked asymmetric septal hypertrophy, but the ventricle is now thinning
and dilating and left bundle branch block has developed. The total extent of hyperenhancement was 25% of the left ventricular (LV) mass. LA left atrium;
RA  right atrial; RV  right ventricle.
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Figure 2. Extent of hyperenhancement and presence of progressive disease. Hyperenhancement was associated with the presence of progressive disease
(A), even when patients at high risk of sudden death were excluded (B), and appeared more marked in patients 40 years old, regardless of the risk of
sudden death (C, D). rfsd  risk factors for sudden death.
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Figure 3. Extent of hyperenhancement and clinical risk factors for sudden death. Hyperenhancement was associated with an increased clinical risk of sudden
death (A), even when patients with progressive disease were excluded (B), and appeared more marked in patients 40 years old, regardless of the presence
of progressive disease (C, D).
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myocardial infarction, fibrosis always includes the subendo-
cardium because of the nature of the ischemic wave front
that starts there. In HCM, gadolinium enhancement could
occur in myocardial replacement fibrosis, but this may
well show different characteristics. First, fibrosis in HCM
can occur throughout the myocardial wall, even with sub-
endocardial sparing. In addition, areas of focal myocardial
disarray and fine interstitial fibrosis may be seen. Therefore,
the distribution and pattern of gadolinium uptake will be
different between these two conditions, as we have con-
firmed in this study.
Histologic correlations between hyperenhancement and
pathology are not yet available. We believe that hyperen-
hancement is the result of a number of pathologic processes
that result in different forms of fibrosis (replacement scar or
myocyte dropout) or in relation to myocardial disarray and
consequent local interstitial expansion. The different pat-
terns of hyperenhancement seen are likely to be linked to
the different pathologic processes occurring in different
patients, and the different stages that such processes had
reached at the time of scanning.
Study limitations. In this preliminary study, the HCM
patients were highly selected, which could introduce a
referral bias. Some patients had both progressive disease
and two or more risk factors for sudden death, but this
reflects the HCM population. Although this compli-
cated the interpretation of the findings, exclusion of
these patients did not alter the results. Future work is
required to identify histologic correlations and prospec-
tive prediction of events based on hyperenhancement find-
ings.
Conclusions. Areas of hyperenhancement are seen in
HCM by CMR. The extent of hyperenhancement is linked
with progressive disease and markers of clinical risk for
sudden death.
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Figure 4. (A and B) Patterns of hyperenhancement in hypertrophic cardiomyopathy by cardiovascular magnetic resonance. The patterns of
hyperenhancement are grouped into diffuse or confluent types (upper rows: long-axis, vertical, or horizontal; lower rows: short-axis views). These were
further subclassified as shown. The different patterns may have clinical or prognostic significance, and this qualitative classification may complement the
overall quantification of hyperenhancement. RV  right ventricular.
Table 2. Associations Between Pattern of Hyperenhancement
and Clinical Phenotype
Type of
Hyperenhancement n (%) Clinical Phenotype
Trans-septal 4 (7%) Young, gross asymmetric LVH;
extensive diffuse
hyperenhancement; high risk of
sudden death
RV septal 4 (7%) Extensive RV surface of septal
hyperenhancement; strong family
history of sudden death
Ventricular junction 12 (23%) Moderate symmetrical LVH; limited
hyperenhancement at RV insertion
points; lower risk of sudden death
Multi-focal 9 (17%) Large focal areas of hyperen-
hancement; LBBB if basal septum;
associated with progressive disease
Subendocardial 2 (4%) Like infarcts, but not IHD, in these
patients
Other 11 (21%) Other patterns or trivial
hyperenhancement
None 11 (21%) Typically young and at low risk
IHD  ischemic heart disease; LBBB  left bundle branch block; LVH  left
ventricular hypertrophy; RV  right ventricular.
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